Xtl Biopharmaceuticals Ltd Stock Buy Hold or Sell Recommendation
| XTLB Stock | USD 2.56 0.03 1.16% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding XTL Biopharmaceuticals Ltd is 'Hold'. Macroaxis provides XTL Biopharmaceutica buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding XTLB positions. The advice algorithm takes into account all of XTL Biopharmaceutica's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting XTL Biopharmaceutica's buy or sell advice are summarized below:
Real Value 2.31 | Hype Value 2.56 | Market Value 2.56 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell XTL Biopharmaceuticals Ltd given historical horizon and risk tolerance towards XTL Biopharmaceutica. When Macroaxis issues a 'buy' or 'sell' recommendation for XTL Biopharmaceuticals Ltd, the advice is generated through an automated system that utilizes algorithms and statistical models.
XTL |
Execute XTL Biopharmaceutica Buy or Sell Advice
The XTL recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on XTL Biopharmaceuticals Ltd. Macroaxis does not own or have any residual interests in XTL Biopharmaceuticals Ltd or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute XTL Biopharmaceutica's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Good | Details | |
Volatility | Abnormally volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
XTL Biopharmaceutica Trading Alerts and Improvement Suggestions
| XTL Biopharmaceutica is way too risky over 90 days horizon | |
| XTL Biopharmaceutica appears to be risky and price may revert if volatility continues | |
| XTL Biopharmaceutica has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (2.25 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| XTL Biopharmaceuticals Ltd currently holds about 5.16 M in cash with (901 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.95. | |
| Latest headline from statnews.com: STAT Day One drug for common childhood brain tumor approved by FDA |
XTL Biopharmaceutica Returns Distribution Density
The distribution of XTL Biopharmaceutica's historical returns is an attempt to chart the uncertainty of XTL Biopharmaceutica's future price movements. The chart of the probability distribution of XTL Biopharmaceutica daily returns describes the distribution of returns around its average expected value. We use XTL Biopharmaceuticals Ltd price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of XTL Biopharmaceutica returns is essential to provide solid investment advice for XTL Biopharmaceutica.
| Mean Return | 2.62 | Value At Risk | -7.37 | Potential Upside | 9.25 | Standard Deviation | 17.15 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of XTL Biopharmaceutica historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
XTL Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as XTL Biopharmaceutica is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading XTL Biopharmaceuticals Ltd backward and forwards among themselves. XTL Biopharmaceutica's institutional investor refers to the entity that pools money to purchase XTL Biopharmaceutica's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Noked Israel Ltd | 2023-12-31 | 198.9 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 39.8 K | Bnp Paribas Arbitrage, Sa | 2023-12-31 | 300 | Guaranty Trust Company Of Missouri | 2023-12-31 | 200 | Ubs Group Ag | 2023-12-31 | 54.0 |
XTL Biopharmaceutica Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 1.2M | (824K) | (662K) | (875K) | (787.5K) | (748.1K) | |
| Free Cash Flow | (910K) | (851K) | (1.0M) | (901K) | (1.0M) | (1.1M) | |
| Other Non Cash Items | 484K | (33K) | (8K) | 451K | 405.9K | 426.2K | |
| Net Income | (1.3M) | (782K) | 435K | (1.3M) | (2.2M) | (2.4M) | |
| End Period Cash Flow | 4.5M | 3.6M | 3.0M | 2.1M | 1.9M | 3.0M | |
| Investments | 2.1M | 32K | 8K | 36K | 32.4K | 30.8K | |
| Change To Netincome | 489K | (114K) | (1.4M) | 447K | 402.3K | 422.4K |
XTL Biopharmaceutica Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to XTL Biopharmaceutica or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that XTL Biopharmaceutica's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a XTL stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 2.24 | |
β | Beta against NYSE Composite | 4.30 | |
σ | Overall volatility | 17.70 | |
Ir | Information ratio | 0.15 |
XTL Biopharmaceutica Volatility Alert
XTL Biopharmaceuticals Ltd is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure XTL Biopharmaceutica's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact XTL Biopharmaceutica's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.XTL Biopharmaceutica Fundamentals Vs Peers
Comparing XTL Biopharmaceutica's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze XTL Biopharmaceutica's direct or indirect competition across all of the common fundamentals between XTL Biopharmaceutica and the related equities. This way, we can detect undervalued stocks with similar characteristics as XTL Biopharmaceutica or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of XTL Biopharmaceutica's fundamental indicators could also be used in its relative valuation, which is a method of valuing XTL Biopharmaceutica by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare XTL Biopharmaceutica to competition |
| Fundamentals | XTL Biopharmaceutica | Peer Average |
| Return On Equity | -0.62 | -0.31 |
| Return On Asset | -0.13 | -0.14 |
| Current Valuation | 1.41 B | 16.62 B |
| Shares Outstanding | 5.45 M | 571.82 M |
| Shares Owned By Institutions | 4.55 % | 39.21 % |
| Number Of Shares Shorted | 437.16 K | 4.71 M |
| Price To Earning | 4.50 X | 28.72 X |
| Price To Book | 5.66 X | 9.51 X |
| EBITDA | (789 K) | 3.9 B |
| Net Income | (2.25 M) | 570.98 M |
| Cash And Equivalents | 5.16 M | 2.7 B |
| Cash Per Share | 0.95 X | 5.01 X |
| Current Ratio | 31.26 X | 2.16 X |
| Book Value Per Share | 0.01 X | 1.93 K |
| Cash Flow From Operations | (901 K) | 971.22 M |
| Short Ratio | 0.89 X | 4.00 X |
| Earnings Per Share | (0.40) X | 3.12 X |
| Target Price | 30.0 | |
| Beta | 1.03 | -0.15 |
| Market Capitalization | 14.11 M | 19.03 B |
| Total Asset | 4.19 M | 29.47 B |
| Retained Earnings | (156.47 M) | 9.33 B |
| Working Capital | 3.62 M | 1.48 B |
| Current Asset | 3 M | 9.34 B |
| Net Asset | 4.19 M |
Note: Acquisition by Edelman Joseph of 17400 shares of XTL Biopharmaceutica at 3.3501 subject to Rule 16b-3 [view details]
XTL Biopharmaceutica Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as XTL . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About XTL Biopharmaceutica Buy or Sell Advice
When is the right time to buy or sell XTL Biopharmaceuticals Ltd? Buying financial instruments such as XTL Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Total Stockholder Equity | 5.3M | 4.0M | 3.6M | 3.4M | Total Assets | 6.6M | 4.2M | 3.8M | 3.6M |
Use Investing Ideas to Build Portfolios
In addition to having XTL Biopharmaceutica in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Automobiles and Trucks Thematic Idea Now
Automobiles and Trucks
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Automobiles and Trucks theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Automobiles and Trucks Theme or any other thematic opportunities.
| View All Next | Launch |
Check out XTL Biopharmaceutica Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Complementary Tools for XTL Stock analysis
When running XTL Biopharmaceutica's price analysis, check to measure XTL Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XTL Biopharmaceutica is operating at the current time. Most of XTL Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of XTL Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XTL Biopharmaceutica's price. Additionally, you may evaluate how the addition of XTL Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
Is XTL Biopharmaceutica's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of XTL Biopharmaceutica. If investors know XTL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about XTL Biopharmaceutica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Earnings Share (0.40) | Return On Assets (0.13) | Return On Equity (0.62) |
The market value of XTL Biopharmaceuticals is measured differently than its book value, which is the value of XTL that is recorded on the company's balance sheet. Investors also form their own opinion of XTL Biopharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is XTL Biopharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because XTL Biopharmaceutica's market value can be influenced by many factors that don't directly affect XTL Biopharmaceutica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between XTL Biopharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if XTL Biopharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, XTL Biopharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.